TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00438399
Drug: C. propionate - Corticosteroid 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application
Study: NCT00438399
Drug: C. propionate- Corticosteroid 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application
Study: NCT00438399
Drug: Corticosteroid 1- C. propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application
Study: NCT00438399
Drug: Corticosteroid 2 - C. propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application
Study: NCT00438399
Drug: Corticosteroid 3 - C. propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application
Study: NCT00479557
Drug: Placebo: Phosphate buffered saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
Study: NCT02235948
Drug: folic acid supplementation
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.8mg folic acid/day
Study: NCT01973452
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04504370
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-119 is an investigational pegylated human glucagon-like peptide-1 (GLP-1) receptor agonist. The dosing regimen is 150μg once every week as subcutaneous administration. Patients in PB-119 group will be administered the active drugs for 52 weeks (24+28).
Study: NCT04504370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-119 matched placebo will be used once every week as subcutaneous administration to placebo group for 24 weeks.
Study: NCT03052842
Drug: C16G2 Strip
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial Peptide
Study: NCT02176291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo
Study: NCT00118729
Drug: GW685698X Aqueous Nasal Spray
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01858610
Drug: Irbeasartan/hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03041909
Drug: GBT440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug
Study: NCT02089620
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a daily placebo similar in size and structure to calvar.
Study: NCT02089620
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
Study: NCT02603185
Drug: Hemay007
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02603185
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004816
Drug: monoclonal antibody M-T412
Normalized name: M
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01814683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days placebo.
Study: NCT00048399
Drug: CAMPATH 1H
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02178293
Drug: Ketoprofen lysine salt
Normalized name: ketoprofen lysine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00050986
Drug: R115777
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
Study: NCT01724112
Drug: LY2940094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01724112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01885078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00789269
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of placebo
Study: NCT00377910
Drug: Aethoxysclerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
Study: NCT03665428
Drug: PAMB treatment (modified quadruple therapy)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly assign either as PAMB or PBMT group treatment
Study: NCT03665428
Drug: PBMT treatment (bismuth-containing quadruple therapy)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomly assign either as PAMB or PBMT group treatment
Study: NCT03415763
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
Study: NCT03415763
Drug: mFOLFOX6 or CAPOX
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
Study: NCT03827590
Drug: Test
Normalized name: Testro
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times a day for five days
Study: NCT00722761
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (no active drug) given once daily for 24 weeks
Study: NCT03827590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times a day for five days
Study: NCT01471860
Drug: Medical Management
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02580604
Drug: Calcium Chloride/Calcium Gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
Study: NCT02580604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Infusion
Study: NCT03004469
Drug: P-3074
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03004469
Drug: P-3074 Vehicle
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03565445
Drug: ASP1948
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously (IV)
Study: NCT02070406
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01549743
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg will be administered orally twice a day for 3 days
Study: NCT01549743
Drug: Celecoxib plus Rebamipide
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide
Study: NCT01628094
Drug: RO5024048
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01628094
Drug: RO5190591
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01628094
Drug: RO5466731
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02207556
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline will be continued until one of the following criteria is met:~* Patient has completed 1 year of doxycycline therapy~* Patient develops any grade 3-4 toxicity related to doxycycline use.
Study: NCT00796133
Drug: NES/E2 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P\<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
Study: NCT02482441
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
Study: NCT02465593
Drug: PEP503
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
Study: NCT02465593
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
Study: NCT01389973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
Study: NCT02289391
Drug: Anesthesia induction
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
Study: NCT02289391
Drug: Anesthesia maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3\~8mg/(kg•h).~* Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30\~40 mmHg and bispectral index (BIS) to 45\~60.
Study: NCT02289391
Drug: Assisted anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
Study: NCT00786929
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03822871
Drug: CTT1403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of 0.75 GBq - 9.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
Study: NCT02418533
Drug: Recominant Follicle Stimulating Hormone (rFSH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonal-f is used for controlled ovarian stimulation (COH)
Study: NCT00803543
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage: Two tablets once a day for 24 weeks
Study: NCT04514159
Drug: ZN-c5
Normalized name: dipentaerythrityl hexa C5-10 acid esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-c5 is the study drug.
Study: NCT04154787
Drug: LNP023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigation of LNP023
Study: NCT00576251
Drug: Tobramycin 0.3%/Dexamethasone 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
Study: NCT00542724
Drug: VIAject™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage as individually required
Study: NCT00542724
Drug: Regular Human Insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage as individually required
Study: NCT03160105
Drug: Switch to DTG + FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from standard cART to DTG + FTC dual maintenance therapy.
Study: NCT01327872
Drug: E5501 40 mg 2 x 20-mg tablets, orally, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
Study: NCT01327872
Drug: E5501 40 mg 2 x 20-mg tablets, orally, with food
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
Study: NCT01327872
Drug: E5501 40mg 2 x 20-mg tablets, orally, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
Study: NCT01327872
Drug: E5501 40 mg 2 x 20-mg tablets, orally, with food
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
Study: NCT01552187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 48 to 72 hours before surgery till 1 months after surgery
Study: NCT02498483
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants will receive 15 mg/kg of acetaminophen.
Study: NCT04352595
Drug: Hemay808
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay808 is a onitment of Hemay028, a small molecule PDE4 inhibitor.
Study: NCT01811355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00311558
Drug: SSG & interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 arm study with SSG \& interferon
Study: NCT01594333
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
Study: NCT01594333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
Study: NCT01682460
Drug: Refresh Tears Lubricant Eye Drops (Allergan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye drops QID for 1 month
Study: NCT02393573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
Study: NCT03298191
Drug: Calcium Channel Blockers
Normalized name: CALCIUM CHANNEL BLOCKERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Those women will be given Calcium Channel Blockers for tocolysis
Study: NCT02559154
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00463190
Drug: Biothree
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02559154
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02559154
Drug: Mitoxsnteone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01925859
Drug: EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)
Approvals — FDA: no, EMA: no, PMDA: no
Description: erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
Study: NCT02379754
Drug: Gentamicins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
Study: NCT04684914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT04802980
Drug: HB002.1T
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB002.1T is a vascular endothelial growth factor receptor decoy
Study: NCT04802980
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is an anti-tumor drug
Study: NCT00917306
Drug: PEP005 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% two day treatment
Study: NCT03054948
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In most cases standard therapy will be IntraLipid.
Study: NCT01887587
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01887587
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00473837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
Study: NCT02896712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsule will be filled with corn starch and riboflavin.
Study: NCT00694694
Drug: azithromycin + artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
Study: NCT00694694
Drug: artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days
Study: NCT01016691
Drug: Placebo Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: device inserted for 4 days
Study: NCT01808690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04095754
Drug: Induction and maintenance of anaesthesia
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim.
Study: NCT00292448
Drug: Ba 679 BR Respimat
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01021852
Drug: Dose-matched Placebo to MK-6096
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
Study: NCT02345031
Drug: AUT00063
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg, orally, once a day, for 4 weeks
Study: NCT02345031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, once a day, for 4 weeks
Study: NCT00138424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control for this study is sterile, 0.9% normal saline for intravenous use.
Study: NCT02517151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01912716
Drug: high dose indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients randomized to this intervention receive 200mg indomethacin
Study: NCT01912716
Drug: standard dose indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients randomized to this intervention receive 100mg indomethacin
Study: NCT03280342
Drug: IR-TPM (Topamax)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-TPM (Trokendi XR)
Study: NCT02193815
Drug: PF06263276
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
Study: NCT00854178
Drug: Comparison of two anesthetic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
Study: NCT00930605
Drug: CHOP regimen alternate with ESHAP regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
Study: NCT00986427
Drug: Refresh® Dry Eye therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion contains glycerin 1% and polysorbate 80
Study: NCT00574496
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02946541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, QD
Study: NCT01527019
Drug: Cephalosporins
Normalized name: First-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
Study: NCT01527019
Drug: Cephalosporins
Normalized name: First-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
Study: NCT01881971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: suger pill manufactured to mimic crestor pills
Study: NCT01881971
Drug: Rouvastatin calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01367873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, matching number of placebo capsule(s) with active arm
Study: NCT03329651
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2
Study: NCT00406783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, once daily for 15 days
Study: NCT00450801
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
Study: NCT00450801
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
Study: NCT00064350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
Study: NCT04396834
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet (BID)
Study: NCT03902782
Drug: Bupivacaine-epinephrine
Normalized name: bupivacaine-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described earlier
Study: NCT03902782
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: As described earlier